A fluorescence polarization immunoassay for barbiturates on the Abbott AxSYM analyzer is described. The assay displayed dilution linearity up to 1200 ng/mL; coefficients of variation varied from 5.96 to 8.61%; recovery varied from 94.9 to 105.3%; and sensitivity was less than 40 ng/mL. Good correlation between the standard six-and factory two-point calibration methods was observed. The immunoassay demonstrated good cross-reactivity to several commonly prescribed barbiturates; low cross-reactivity with structurally similar compounds; low interference from endogeneous substances, dyes, preservatives, and several commonly available adulterants; and good correlation with the TDx Barbiturate Urine assay.
Introduction
Frequently administered on a therapeutic basis as sedatives, hypnotics, and anticonvulsants, barbiturates are central nervous system (CNS) depressants that have been known since the early 1900s when first introduced into therapeutic use by Fisher and von Meting (1) . Disubstitution at the 5-position is required for CNS activity because unsubstituted and 5-monosubstituted barbituric acids demonstrate no pharmacological activity. Small variations in the structure of the 5-substituents and substitution of the 1,3-imido hydrogens can result in significant changes in the drug's physiological effects and duration (2) . Frequently abused barbiturates include butalbital, amobarbital, secobarbital, pentobarbital, and phenobarbital (2) (Figure 1 ). Because of their CNS activity, these barbiturates have been frequently used to commit suicide either alone or in combination with other drugs (3, 4) .
An ideal analytical method would allow for the rapid determination of the presence or absence of a variety of barbiturates with slightly different structures. Several methods for the determination of barbiturates have been developed (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Competitive-binding immunoassay techniques offer advantages over chromatographic *Author to whom correspondence should be addressed. E-mail maciej.adamczyk@abbott.com.
techniques such as gas chromatography, high-performance liquid chromatography, and capillary electrophoresis because chromatographic techniques first require sample extraction, frequently require sophisticated equipment, and possess lengthy assay time requirements (20) . Immunoassay methods such as enzyme immunoassay (EIA) and substrate-linked fluorescence immunoassay (SLFIA) each contain enzymes that can be sensitive to enzyme inhibitors or influenced by other reactive enzymes contained in the sample (21) , whereas radioimmunoassay (RIA) possesses other disadvantages, including reagents with short shelf lives and the hazards of working with, storing, and disposing of radioactive materials (22) . Fluorescence polarization immunoassay (FPIA) is easily automated and employs fluorescent tracers and antibodies, thus avoiding the shortcomings associated with enzyme sensitivity and the hazards of radiolabeled tracers (23) .
Previously, we developed an fluorescence polarization screening immunoassay for barbiturates (24) that demonstrated observable cross-reactivities with phenytoin and its major metabolite 5-(phydroxyphenyl)-5-phenylhydrantoin (p-HPPH) and nonsteroidal anti-inflammatories such as fenoprofen, ibuprofen, and naproxyn (25) (26) (27) . The ready availability of these drugs required a different approach that would result in the elimination of cross-reactivities.
Here we describe an FPIA screening assay for detecting different types of barbiturates. Using immunoassay reagents that were designed with the help of molecular modeling (28) , the method Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. 
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shows good cross-reactivity with several important barbiturates, low interference from structurally similar compounds and the anti-inflammatories alluded to here, and good correlation with the TDx Barbiturates Urine assay.
Methods

Materials
Analytically pure secobarbital was purchased from Sigma Chemical (St. Louis, MO). Cyclopentobarbital was purchased from Alltech Associates (Deerfield, IL); brallobarbital was purchased from UCB Pharmaceuticals (Brussels, Belgium); and talbutal was purchased from USP (Rockville, MD). Other barbiturates were purchased from Sigma Chemical. A barbiturate hapten linked to bovine serum albumin to form an immunogen was injected into sheep to provide the antisera against barbiturates (27) . The fluoresceinated barbiturate tracer was prepared as previously described (27) . Cross-reactants were purchased from Sigma Chemical, Aldrich Chemical (Milwaukee, WI), Alltech Associates, and USP, or obtained from Abbott Laboratories (North Chicago, ILL AxSYM disposables and accessories and TDx disposables and accessories were obtained from Abbott Laboratories (]wing, TX).
Patient specimens
Human patient specimens (urine) were purchased from a variety of laboratories in a volume sufficient to allow for both TDx and AxSYM analysis. Patient identity was removed from samples prior to receipt at the laboratory. At time of arrival, aliquots were irnmediately removed from the samples for TDx and AxSYM analysis. Samples and aliquots delayed in analysis for more than 48 h were stored at -20~ (29) .
AxSYM analysis
An AxSYM instrument (Abbott Labs) equipped with Revision 2.0 so~,are using AxSYM line diluent (0.1M phosphate buffer, pH 7.4, with 0.1% of a proprietary antimicrobial agent) was employed for identification of barbiturate samples. Assay parameters are shown in Table I . Controls were prepared from analytically pure secobarbital at concentrations of 300, 800, and 1500 ng/mL (low, medium, and high controls, respectively) in normal human urine diluent containing 0.1% sodium azide. Polarization measurements are reported as millipolarization (mP) units. A standard curve was generated using calibrators prepared gravimetrically from analytically pure secobarbital at assigned concentrations of 0, 200, 400, 700, 1200, and 2000 ng/mL (A, B, C, D, E, and F calibrators, respectively). Calibrator concentrations were independently verified by mass spectrometry. The calibrator matrices were the same as described here for the controls. The data in Figure 2 are the means of duplicate determinations using a logistical four-parameter curve fit. Mean calibrator responses were established by using multiple instruments and stored during manufacture in barcode form on 100,000 100,000 100,000 1,000,000 100 000 100 000 100 OOO 100 000 100 000 100 000 100 000 100 000 100 000 I00 000 100 000 100,000 100,000 100,000 100,000 100,000 100,000 100,000 1,000,000 100,000 3,000,000 100,000 1,000,000 100,000 1,000,000 1,000,000 100,000 1,000,000 100,000
100,000 100,000 I00,000 each reagent lot. The two-point master calibration curve was thus derived specifically for each reagent lot and refit the standard sixpoint calibration curve based on the instrument response to the two-point curve (30, 31) . A patient sample, control, or cross-reactant at a concentration indicated in Tables II-IV (100-150 mL) was pipetted into the sample cup of an AxSYM cartridge. Serial dilutions of patient samples were prepared and pipetted into the sample cup of an AxSYM cartridge and analyzed to evaluate dilution linearity. Dilutions were made by diluting the sample with the A calibrator. The sensitivity of the assay was determined by identifying the lowest measurable concentration of drug in human urine that could be distinlOO,OO0 guished from a sample known to contain 0 nNmL lOO, OOO of the drug with a 95% confidence limit (n = 20). loo,ooo
Replicates of a clinical sample known to be nega-1 oo,ooo tire for barbiturates and the A calibrator were both analyzed. The standard deviation of the replicates 100,000
was then calculated, and twice this number was subtracted from the average of the replicates in 1 oo, ooo each case.
TDx analysis
A TDx FPIA instrument (Abbott Labs) equipped with Revision 15 software using TDx dilution buffer (0.1M phosphate buffer, pH 7.4, with 0.1% bovine gamma globulin and 0.1% sodium azide) was employed for comparison with the AxSYM assay. Assay parameters are shown in 'fable I. Controls were prepared from analytically pure secobarbital at concentrations of 0.60 and 1.00 mg/mL (low and high controls, respectively) in normal human urine containing 0.1% sodium azide. Polarization measurements are reported as millipolarization units.
Standard curves were generated from calibrators prepared gravimetrically from analytically pure secobarbital at assigned concentrations of 0, 0.20, 0.40, 0.70, 1.20, and 2.00 mg/mL (A, B, C, D, E, and F calibrators, respectively). The calibrator matrices were the same as described ff)r the controls. Samples were pipetted directly into the sample wells.
Results
AxSYM analysis
A calibration curve was generated for the barbiturate assay (Figure 2 ) using calibrators that contained secobarbital. Dilution linearity of the AxSYM barbiturate assay was demonstrated with barbiturate-free patient samples spiked with secobarbital to 1200 and 2000 ng/mL. The samples were serially diluted five times (1:32) with normal human urine (calibrator A). The patient samples yielded slopes of 1.00-1.01 and R > 0.99 (Figure 3 ). Intercepts were less than the sensitivity of the assay in all cases.
The precision of the barbiturate AxSYM assay was determined by assaying the three controls (low, medium, and high) in duplicate on each of 40 runs over a 20-day period (two runs per day) using four different AxSYM analyzers (32). The results are shown in Table V . Overall coefficients of variation (CV) varied from 5.9 to 8.6%. Additionally, the correlation between two-point (master calibration) and standard six-point calibration was assessed. The correlation between the two methods of assay calibration was excellent (Figure 4) , showing R = 0.997 and slope = 1.000 (31) . Sensitivity of the assay was determined by identifying the lowest measurable concentration of drug in human urine that could be distinguished from a sample known to contain 0 ng/mL of the drug with a 95% confidence limit (n = 20). Using the twopoint calibration curve, the negative urine yielded a value of 34 ng/mL, and calibrator A yielded 37 ng/mL. With a six-point calibration curve, values of 24 and 27 ng/mL were obtained (ANOVA < 0.05). These values are statistically indistinguishable. The assay was thus able to detect concentrations of secobarbital at less than 40 ng/mL.
As shown in Table II , good cross-reactivity was obtained with a number of different barbiturates, including both aliphatic and aromatic 5-substituents. The concentrations of barbiturates tested were chosen to provide clinically useful impressions; higher concentrations were used if needed to provide a detectable signal. Thus, cross-reactivity with compounds structurally similar to barbiturates was low (Table III) , demonstrating the specificity of the antiserum. Percent cross-reactivity was calculated as 100 x (measured concentration of the test compound -the added concentration of the test compound).
A wide variety of other types of drugs showed negligible crossreactivity in the AxSYM Barbiturates I] Urine Assay (Table IV) . Potential interference from commonly available adulterants, endogeneous substances, fluorescent dyes, and preservatives was minimal. Concentrations of acetone (1.0 g/dL), ethanol (1.00 g/dL), ascorbic acid (1.5 g/dL), glucose (2.0 g/dL), oxalic acid (100 mg/dL), sodium chloride (6 g/dL), bilirubin (0.25 mg/dL), creatinine (0.5 g/dL), hemoglobin (115 mg/dL), riboflavin (7.5 mg/dL), protein (50 IJg/dL), urea (6 g/dL), fluoresceine, rhodamine, eosin Y, acriflavin (all dyes at I > 30,000), sodium azide (0.1% w/v), boric acid (0.1% w/v), and sodium fluoride (0.13 mg/mL) resulted in less than 10% error.
Percent recovery was measured by adding a known amount of the drug to be assayed to human urine confirmed to be negative for barbiturates and AxSYM diluent buffer. Percent recovery was calculated as 100 x (concentration measured in buffer + concentration measured in urine). The calculated recoveries ranged from 95 to 105%. The results are shown in Table VI . Concordance between the TDx and AxSYM assays was evaluated at several cutoffs and calculated by dividing the sum of true positives and true negatives by the sum of true and false positives plus true and false negatives.
Comparison of analyses
As can be seen in Table I , the calibrator concentrations are the same for each assay. The AxSYM assay does use a slightly larger sample volume (25 IJL vs. 10 IJL), but it achieves a larger dynamic range (107 mP vs. 86 raP), which results in increased assay precision.
A total of 100 samples known to contain barbiturates (confirmed by gas chromatography-mass spectrometry by Aegis Analytical Laboratories, Nashville, TN) were assayed by the AxSYM analyzer and compared with results obtained by the TDx on the same sampies. Fifty-five samples showed greater than 2000 ng/mL by both assays. Linear regression analyses was performed on the remaining samples, and gave the following parameters for the assay: correlation coefficient = 0.9927, slope = 1.009, y-intercept = 37.586. This correlation is shown in Figure 5 . Assay concordance for the AxSYM assay versus TDx was 100% at 200 ng/mL, 100% at 400 ng/mL, and 98% at 700 ng/mL.
Discussion
The ideal screening assay for barbiturates would be rapid and automated, and it would detect frequently abused barbiturates with equivalent recognition at similar concentrations. Screening immunoassays require antibodies with a broad recognition of the Class of molecules of interest. For barbiturates, three different structural elements are important for optimal recognition: the pyrimidinetrione (barbiturate) ring, the larger 5-substituent, and the smaller 5-substituent. Although the smaller 5-substituent shows little variability (generally ethyl or allyl), considerable vari- ation is observed in the larger 5-substituent (e.g., isopropyl, isobutyl, isopentyl, sec-pentyl, phenyl, etc.) (Figure 1 ). The immunoassay described here uses a polyclonal antibody, which is ideal for a screening application because of its ability to recognize a variety of structural features with subtle structural differences (28) . This assay for the detection of barbiturates in urine was designed to be run on the AxSYM analyzer because it offers several advantages over the older TDx instrument. Although both instruments accommodate the time-tested homogeneous FPIA technology, the AxSYM analyzer also is capable of processing heterogeneous microparticle enzyme immunoassay (MEIA) and ion-capture immunoassay (ICIA) technologies (30) . Because the AxSYM is a continuous, random-access analyzer possessing 20 onboard assays, it is capable of simultaneously analyzing large numbers of a variety of samples. Samples can be loaded directly from primary sampling tubes in any order, even after processing has been initiated; assay reagents can be replenished at any time. For the TDx, as with any batch analyzer, samples have to be sorted and grouped with other samples requiting the same assay and can only be run in sets of 20 samples. The addition of reagents or samples during processing is not possible. The new AxSYM design provides greater flexibility for assay development; requires less operator attention; and results in improved laboratory workflow, a higher throughput, and faster turnaround time. In a batch mode, 80 to 120 tests can be processed in about 60 rain; in combination with other samples, assay times are slightly longer.
For this assay, calibration curves were constructed using either six (standard) or two (Master) calibrators containing analytically pure secobarbital and a four-parameter logistical curve fit. The standard curve covers the relevant range for barbiturates. The total CV ranges were 5.1-11.3% at the 95% confidence level across multiple instruments and multiple lots. All y-intercepts were below a diagnostically relevant cutoff (established as < 60 ng/mL).
This assay was designed to identify a variety of barbiturates. Assay specificity relies on the ability of the polyclonal antisera to distinguish between barbiturates and similar substances. The data in Tables II-IV indicate the cross-reactivities of various compounds with these antisera. Good cross-reactivity was obtained in the AxSYM assay with a number of different barbiturates, including those containing both aliphatic and aromatic 5-substituents (Table II) . Of the 18 barbiturates tested, 12 demonstrated crossreactivities of greater than 22%. Secobarbital was selected as the calibrator for the assay, and thus showed 100% cross-reactivity. The relatively higher recognition demonstrated by secobarbital and aiphenal, which contain a 5-allyl group, as compared with pentobarbital and phenobarbital, which are structurally identical except for their 5-ethyl group (Figure 5 ), indicates that barbiturates containing a 5-ally1 group demonstrate better recognition than barbiturates containing a 5-ethyl group. Talbutal contains a branched 5-isobutyl group, which is larger than the 5-isopropyl group of aprobarbital, the 5-bromoallyl group of brallobarbital, and the unbranched 5-allyl group of allobarbital, and therefore has the best cross-reactivity of the four barbiturates. Size and branching of the larger 5-substituent are thus observed to be important factors in evaluating barbiturate cross-reactivity.
Barbital, thiopental, and 5-ethyl-5-(4-hydroxyphenyl)barbituric acid (a phenobarbital metabolite) showed low (3-7%) cross-reactivity, and hexobarbital, metharbital, and methohexital showed very low cross-reactivity (< 1%; Table II ). Thiopental has a sulfur in place of one of the barbiturate ring oxygens and thus shows lower cross-reactivity than its structural analogue, secobarbital.
Also, 5-ethyl-5-(hydroxyphenyl)barbituric acid is similar to phenobarbital, but it has an aromatic hydroxyl on the 5-substituent and, consequently, a lower cross-reactivity. Metharbital, methohexital, and hexobarbital all showed very low cross-reactivity (observable only at extremely high concentrations). This is not surprising in view of the fact that these barbiturates each have an N-methyl group present on the barbiturate ring in place of one of the pyrimidinetrione hydrogens and thus appear very dissimilar structurally when compared with other barbiturates.
Cross-reactivity was also evaluated with structurally similar compounds ('Fable Ill). Although most of these compounds (including p-HPPH) showed very low (< 1%) cross-reactivities, only the rarely prescribed glutethimide showed cross-reactivity (4.5%) when tested at high concentrations. Because none of these compounds contains a barbiturate ring, the importance of the barbiturate ring in determining recognition can clearly be observed. Table IV is an extensive list of the different drugs that show negligible interference with the detection of barbiturates, including fenoprofen, ibuprofen, naproxyn, and phenytoin. Thus, this assay produced negligible cross-reactivity with the drugs that had previously been demonstrated to be problematic for the earlier TDx assay.
Endogeneous substances, dyes, preservatives, and common chemical and solvent adulterants were also tested and showed minimal interference. Patient samples analyzed by AxSYM showed good correlation (slope = 1.009; constant 37.586; R = 0.993;) ( Figure 5 ) and high concordance with the TDx FPIA.
In conclusion, we have described a rapid, random-access assay for the semiquantitative detection of barbiturates in urine using the well-established homogeneous FPIA technology on the Abbott AxSYM analyzer. The assay described here shows good sensitivity, good precision by two-or six-point calibration, and low interferences. This assay shows little cross-reactivity to compounds other than barbiturates, particularly phenytoin, p-HPPH, and the previously noted nonsteroidal anti-inflammatories, and correlates well to the TDx Barbiturates assay. In a batch mode, 90 samples can be processed in about 60 rain. In combination with other samples, assay times are slightly longer (77 samples/h or greater).
